Ever Supreme Bio Technology announced October revenue of $59.12 million, an annual increase of 15.5%, and cumulative revenue of $506 million for the first ten months of this year, already surpassing last year's annual performance of $438 million. Chairman of the Board, Mr. Liu Ba-qi (劉銖淇), said on the 3rd of October that Ever Supreme has been launching new autologous cellular products and the preparation time has been significantly shortened, which has led to the increasing acceptance of cellular therapy by patients, and he is optimistic that both revenue and profit will grow year on year.
The company has reported revenue of $59.12 million in October, an increase of 15.5% year-on-year. The company's results have grown positively for nine consecutive months since February this year, and the corporation estimates that it will successfully surpass the $600 million mark for the year.
The first is a series of autologous cell therapy products that have passed the Special Administrative Law, and currently there are 15 partner hospitals with patient schedules until the second quarter of next year. One of the key points of the new autologous cell products is to shorten the preparation time. For example, the preparation time of the early immune cell product DC took three months, but the preparation time of the DC-CIK product has been reduced to one and a half months, and the preparation time of the latest product Gamma Delta-T (GDT) launched this year can be shortened to three to four weeks, which is crucial for cancer patients who are in a daily race against time.
According to Liu, there are about 40,000 cancer patients a year in Taiwan, and Ever Supreme has only served about 200-300 patients this year, so there is plenty of room for growth. The auto-immune cell therapy products offered by Ever Supreme, be it DC or DC-CIK, can achieve a control rate of up to 70% when combined with other therapies for patients with terminal cancer. In addition, the company's two existing cellular manufacturing plants are nearly full, and with the approval of the third plant next year, the company will be able to grow its operations even more.
Another of Ever Supreme's business activities is the development of allogeneic cell therapy, of which UMSC01, the umbilical cord mesenchymal stem cell for acute myocardial infarction, is currently applying for Phase II clinical trials in Taiwan and the US, with an estimated implementation time of three years. If the Phase II clinical trial can be successfully completed, it will be able to obtain a five-year temporary drug license if the Regenerative Medicine Act is passed in Taiwan.
Another of Ever Supreme's allogeneic cell therapy projects is CAR-T, which is one of the few projects in the world targeting solid tumours. The study has already passed the pre-IND Pre-IND (pre-submission consultation for human clinical trials) and will be ready to apply to the FDA for Phase I/IIA clinical trials in Taiwan and the US by the end of this year at the earliest.
Chairman Liu said that the two allogeneic cell therapy technology platforms, UMSC01 and CAR-T, are currently under negotiation with the international industry for licensing and technology transfer in overseas markets. However, he expects to see the completion of the licensing of the CAR-T technology at the end of the first phase of clinical development, in order to maximize the licensing amount.
